Stereotactic radiation therapy for patients with 6 to 10 metastatic sites
Official title: OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients (6-10 Metastases): A Prospective Phase II Single-Arm Trial
Run by National Medical Research Radiological Centre of the Ministry of Health of Russia · NCT06856603 · Data updated 2026-11-12
This study is testing a new type of targeted radiation therapy for people with metastatic cancer who have 6 to 10 tumor sites to see if it can help them live longer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | National Medical Research Radiological Centre of the Ministry of Health of Russia Academic / other |
| Drugs / interventions | radiation, chemotherapy, immunotherapy |
| Locations | 1 site (Obninsk, Kaluga Oblast) |
| Status | Recruiting |
| Started | February 7, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2030 |
| Registry record updated | March 4, 2025 |
| Trial ID | NCT06856603 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with persistent or progressive cancer disease and 6 to 10 metastases who are not eligible for surgical resection.
✕Probably not a fit
Patients with ECOG status 4, de novo metastatic disease, or those who have had previous radiation therapy for any metastatic site may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and effectiveness of stereotactic ablative radiation therapy in patients with metastatic cancer who have between 6 to 10 metastatic sites. Patients will undergo advanced imaging and dosimetric planning to target their tumors with high precision radiation. The treatment aims to improve overall survival in a patient population that has not been extensively studied in previous trials. The approach is based on emerging evidence suggesting benefits of radiation therapy in oligometastatic disease.
Why it matters
Potential benefit: If successful, this treatment could significantly improve survival rates for patients with multiple metastatic sites.
How similar studies have gone: Other studies have shown success with stereotactic ablative radiation therapy for fewer metastatic sites, but this specific approach for 6 to 10 metastases is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ECOG status 0-3 * Persistent or progressive cancer disease with 6 to 10 metastases * ≤ 5 metastases in one organ * Life expectancy \> 6 months for intracranial lesions * Inability to surgically resect all metastatic lesions * Positive tumor board decision for trial inclusion * Signed informed consent Exclusion Criteria: * ECOG status 4 * De novo metastatic disease * Radiological complete response after drug therapy * Brain metastasis only * Brain metastasis \> 3 cm, requiring neurosurgery * Size of any metastasis \> 5 cm * Previous radiation therapy for any metastatic site * Leptomeningeal, pleural, or peritoneal carcinomatosis * Spinal cord compression, requiring neurosurgery * Invasion of great vessels, skin, or GI tract * Negative tumor board decision for trial inclusion * Unsigned informed consent
Where it's running
-
A. Tsyb Medical Radiological Research Center
Obninsk, Kaluga Oblast, Russia Recruiting
Study contacts
- Study coordinator: Konstantin gordon, PhD
- Email: dr_gordon@yahoo.com
- Phone: 0079105184148
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dual-target CAR-NK cells targeting MSLN + MUC1 or CLDN18.2 + MUC1 in advanced PDAC
Aimed at people with advanced pancreatic cancer, this trial tests two off-the-shelf CAR-NK cell products to see if they are safe and can slow or shrink tumors.
-
PSMA-targeted fluorescent dye OTL78 to guide prostate cancer surgery
This study tests whether the PSMA-targeted fluorescent dye OTL78, used with near-infrared imaging, can help doctors better find and remove prostate cancer tissue during surgery in men with confirmed prostate cancer.
-
Using PSMA PET with MRI to watch for prostate cancer returning after focal therapy
We will try adding a PSMA PET scan to routine MRI follow-up to see if it finds prostate cancer coming back sooner in men who had focal (partial gland) therapy.
-
Mini-tumors to guide treatment for aggressive prostate cancer
We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.
-
Combining radiotherapy or surgery with intense hormone therapy for advanced prostate cancer
This study is testing if combining surgery or radiation with strong hormone therapy can help men with newly diagnosed advanced prostate cancer feel better and live longer.
-
SRT for bone and lymph node metastases in advanced prostate cancer
This trial tests whether treating multiple metastatic lesions with stereotactic radiotherapy can prolong pain control and prevent complications in men with advanced, treatment‑refractory prostate cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.